

# VU Research Portal

## Bridging the gap

Iqbal, Ramsha

2023

**DOI (link to publisher)**  
[10.5463/thesis.292](https://doi.org/10.5463/thesis.292)

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Iqbal, R. (2023). *Bridging the gap: from methodological developments towards clinical implementation of imaging biomarkers in lung and breast cancer*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam]. <https://doi.org/10.5463/thesis.292>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## TABLE OF CONTENTS

<b>Chapter 1.</b>	<b>Introduction</b>	<b>11</b>
<b>Part I: Lung cancer</b>		
<b>Chapter 2.</b>	Multiparametric analysis of the relationship between tumor hypoxia and perfusion with $^{18}\text{F}$ -fluoroazomycin arabinoside and $^{15}\text{O}$ - $\text{H}_2\text{O}$ PET	23
<b>Chapter 3.</b>	Validation of $^{18}\text{F}$ -FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor	45
<b>Part II: Breast cancer</b>		
<b>Chapter 4A.</b>	Biodistribution of $^{18}\text{F}$ -FES in patients with metastatic ER+ breast cancer undergoing treatment with rintodestrant (G1T48), a novel selective ER degrader	69
<b>Chapter 4B.</b>	$^{18}\text{F}$ -FES uptake in the pituitary gland and white matter of the brain	93
<b>Chapter 5.</b>	Kinetic modeling of $^{18}\text{F}$ -FES PET in patients with metastatic ER+ breast cancer	99
<b>Chapter 6.</b>	Diagnostic performance of $^{18}\text{F}$ -FDG PET in staging grade 1–2, estrogen receptor positive breast cancer	129
<b>Chapter 7.</b>	$^{18}\text{F}$ -FDG and $^{18}\text{F}$ -FES PET/CT imaging as a biomarker for therapy effect in patients with metastatic ER+ breast cancer undergoing treatment with rintodestrant	161
<b>Chapter 8.</b>	<b>Summary, discussion and future perspectives</b>	<b>193</b>
<b>Part III: Addendum</b>		
	Dutch Summary	211
	Acknowledgements	219
	Curriculum Vitae	225
	List of publications, awards and grants	227
	List of abbreviations	229